---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-294454"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T16:54:06.615292+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Personalis gets CMS revised reimbursement rates for NeXT Personal breast cancer test

## Summary
- CMS revised reimbursement for Personalis' NeXT Personal Dx Breast MRD test to $4,266 effective Dec 1, 2025
- Reimbursement for NeXT Personal Single Plasma Test set at $1,164, available up to six years post-treatment
- Medicare coverage for the NeXT Personal Dx test is available once per cancer diagnosis for stage II/III breast cancer

## SEC filing metadata
- accession: 0001193125-25-294454
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312525294454/0001193125-25-294454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312525294454/d937100d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-294454
- JSON: https://secwatch.observer/filing/0001193125-25-294454.json
- Plain text: https://secwatch.observer/filing/0001193125-25-294454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.